New 4-Drug cocktail aims to crush myeloma that Won't stay away
NCT ID NCT05896228
First seen Mar 28, 2026 · Last updated May 12, 2026 · Updated 6 times
Summary
This study tests a combination of four drugs (iberdomide, daratumumab, carfilzomib, and dexamethasone) in adults whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if this mix can shrink the cancer to very low levels and keep it from returning. About 30 participants will receive the treatment and be monitored for side effects and how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.